Лекарственно-индуцированная эозинофилия
https://doi.org/10.30895/2312-7821-2019-7-4-176-189
Аннотация
Эозинофилия может быть вызвана разными причинами, в том числе приемом лекарственных средств. Актуальность изучения проблемы лекарственно-индуцированной эозинофилии обусловлена тяжелыми последствиями, ассоциированными с данным состоянием, в частности эозинофилией-миалгией, DRESS-синдромом, поражением сердца и мультисистемными проявлениями, которые могут привести к летальному исходу. Цель работы: анализ и систематизация данных о факторах риска развития лекарственно-индуцированной эозинофилии и ее распространенности при применении различных групп лекарственных средств, а также обобщение информации о существующих способах профилактики и коррекции данного состояния. Установлено, что наиболее часто лекарственно-индуцированная эозинофилия развивается на фоне приема антибиотиков групп пенициллинов, цефалоспоринов, тетрациклинов, а также сульфаниламидов, противомалярийных, противолепрозных, противосудорожных и нестероидных противовоспалительных препаратов. Систематизированы данные о распространенности лекарственно-индуцированной эозинофилии при использовании лекарственных средств различных групп с указанием типа реакции и тяжести состояния. Данное патологическое состояние встречается у пациентов всех возрастных категорий, с одинаковой частотой как у мужчин, так и у женщин. К факторам риска возникновения лекарственно-индуцированной эозинофилии относят наличие ряда клональных заболеваний крови, некоторых других заболеваний (аллергических и атопических), инфекций (особенно паразитарных), опухолей, а также одновременный прием двух или более лекарственных средств из указанных выше групп. Бессимптомная эозинофилия не требует прекращения проводимой медикаментозной терапии. При наличии клинической симптоматики, связанной с эозинофилией, препарат целесообразно отменить или заменить, а при невозможности этого лечение продолжают на фоне обязательного мониторинга клинической картины и гематологических показателей. Для обеспечения адекватной профилактики и ранней диагностики лекарственно-индуцированной эозинофилии необходимо повышать информированность практикующих врачей разных специальностей о возможности развития такой нежелательной реакции на фоне фармакотерапии.
Ключевые слова
Об авторах
О. Д. ОстроумоваРоссия
Остроумова Ольга Дмитриевна, доктор медицинских наук, профессор
ул. 1-я Леонова, д. 16, Москва, 129226; ул. Делегатская, 20/1, Москва, 127423
Е. Ю. Шахова
Россия
Шахова Екатерина Юрьевна
ул. Делегатская, 20/1, Москва, 127423
А. И. Кочетков
Россия
Кочетков Алексей Иванович, кандидат медицинских наук
ул. 1-я Леонова, д. 16, Москва, 129226
Список литературы
1. Berkow R, Fletcher AJ, eds. The Merck manual of diagnosis and therapy. 16th ed. Rahway: Merck Research Laboratories; 1992.
2. Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1995.
3. Maidment I, Williams C. Drug-induced eosinophilia. Pharm J. 2000;264(7078):71–6.
4. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301–8. https://doi.org/10.1016/j.alit.2019.03.006
5. Watanabe H. Recent advances in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Immunol Res. 2018;2018:5163129. https://doi.org/10.1155/2018/5163129
6. Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49(2):149–59. https://doi.org/10.1053/j.seminhematol.2012.01.006
7. Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, Walensky RP, Nelson SB. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J Allergy Clin Immunol. 2015;136(5):1288–94.e1. https://doi.org/10.1016/j.jaci.2015.04.005
8. Rauscher C, Freeman A. Drug-induced eosinophilia. Allergy Asthma Proc. 2018;39(3):252–6. https://doi.org/10.2500/aap.2018.39.4120
9. Lopez M, Salvaggio JE. Eosinophilic pneumonias. Immunol Allergy Clin North Am. 1992;12(2):349–63.
10. Jessop JD, Dippy J, Turnbull A, Bright M. Eosinophilia during gold therapy. Rheumatology. 1974;13(2):75–80. https://doi.org/10.1093/rheumatology/13.2.75
11. Edelman J, Davis P, Owen ET. Prevalence of eosinophilia during gold therapy for rheumatoid arthritis. J Rheumatol. 1983;10(1):121–3.
12. Савочкина ДИ. DRESS-синдром (DIHS-синдром): этиология, патогенез, симптомы. Международный студенческий научный вестник. 2018;(4):298–300.
13. Воржева ИИ, Черняк БА. Поражения легких при системной реакции лекарственной гиперчувствительности с эозинофилией: обзор литературы и клинические наблюдения. Практическая пульмонология. 2018;(2):59–68.
14. Moshari J, Niazkar HR, Shahri MK, Ghorbani M, Darafshi R. Drug-induced eosinophilia secondary to the cotrimoxazole administration in acute brucellosis. Asian J Pharm Clin Res. 2018;11(9):3–4. http://dx.doi.org/10.22159/ajpcr.2018.v11i9.25610
15. Morrisroe K, Wong M. Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis. Rheumatology. 2015;54(11):2113–4. https://doi.org/10.1093/rheumatology/kev275
16. Broccolo F, Ciccarese G, Picciotto A, Drago F. A case of drug rash with eosinophilia and systemic symptoms (DRESS) induced by telaprevir associated with HHV-6 active infection. J Hepatol. 2015;62(1):248–9. https://doi.org/10.1016/j.jhep.2014.09.014
17. Демко ИВ, Собко EA, Ищенко ОП, Соловьева ИА, Крапошина АЮ, Аристархова ЛВ и др. DIHS/DRESS синдром, вызванный карбамазепином. Лечение и профилактика. 2016;3(19):56–9.
18. Шаленкова МА, Михайлова ЗД. Эозинофилия как осложнение длительного приема кордарона. Медицинский альманах. 2009;(1):215–8.
19. Kowalszki A, Sheikh J, Weller PF. Eosinophils and eosinophilia. In: Rich RR, ed. Clinical immunology: principles and practice. 4th ed. London: Elsevier Saunders; 2013. P. 298–309.
20. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–93. https://doi.org/10.7326/0003-4819-139-8-200310210-00012
21. Wykoff R. Eosinophilia. Southern Med J. 1986;79(5):608–12. https://doi.org/10.1097/00007611-198605000-00021
22. Spry CJF. Eosinophilia and allergic reactions to drugs. Clin Haematol. 1980;9(3):521–34.
23. Girard JP, Kunz ML, Kobayashi S, Rose NR, Arbesman CE. Penicillin hypersensitivity with eosinophilia: a case report with immunologic studies. Am J Med. 1967;42(3):441–8. https://doi.org/10.1016/0002-9343(67)90272-0
24. Romano A, Di Fonso M, Pocobelli D, Giannarini L, Venuti A, Garcovich A. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to beta-lactam antibiotics. J Investig Allergol Clin Immunol. 1993;3(1):53–5.
25. Fenoglio JJ Jr, McAllister HA Jr, Mullick FG. Drug related myocarditis: I. Hypersensitivity myocarditis. Hum Pathol. 1981;12(10):900–7. https://doi.org/10.1016/s0046-8177(81)80195-5
26. Felman RH, Sutherland DB, Conklin JL, Mitros FA. Eosinophilic cholecystitis, appendiceal inflammation, pericarditis, and cephalosporin-associated eosinophilia. Dig Dis Sci. 1994;39(2):418–22. https://doi.org/10.1007/bf02090217
27. Verma S, Kieff E. Cephalexin-related nephropathy. JAMA. 1975;234(6):618–9. https://doi.org/10.1001/jama.1975.03260190046023
28. Smith JH, Weinstein VF. Cephalexin associated pulmonary infiltration with circulating eosinophilia. Br Med J (Clin Res Ed). 1987;294(6574):776. https://doi.org/10.1136/bmj.294.6574.776-d
29. Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. Pharmacotherapy. 1997;17(6):1341–4.
30. Hannah B, Kimmel P, Dosa S, Turner M. Vancomycin-induced toxic epidermal necrolysis. South Med J. 1990;83(6):720–2. https://doi.org/10.1097/00007611-199006000-00035
31. Frye RF, Job ML, Dretler RH, Rosenbaum BJ. Teicoplanin nephrotoxicity: first case report. Pharmacotherapy. 1992;12(3):240–2.
32. Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010;62(2):315–8. https://doi.org/10.1016/j.jaad.2009.05.046
33. Sitbon O, Bidel N, Dussopt C, Azarian R, Braud ML, Lebargy F, et al. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med. 1994;154(14):1633–40. https://doi.org/10.1001/archinte.1994.00420140105013
34. Parneix-Spake A, Bastuji-Garin S, Lobut JB, Erner J, Guyet-Rousset P, Revuz J, Roujeau JC. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol. 1995;131(4):490–1. https://doi.org/10.1001/archderm.1995.01690160120024
35. Maubec E, Wolkenstein P, Loriot MA, Wechsler J, Mulot C, Beaune P, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology. 2008;216(3):200–4. https://doi.org/10.1159/000112926
36. Ho D, Tashkin DP, Bein ME, Sharma O. Pulmonary infiltrates with eosinophilia associated with tetracycline. Chest. 1979;76(1):33–6. https://doi.org/10.1378/chest.76.1.33
37. Lorber B, Cutler C, Barry WE. Allergic rash due to amphotericin B. Ann Intern Med. 1976;84(1):54. https://doi.org/10.7326/0003-4819-84-1-54
38. Asperilla MO, Smego RA Jr. Eosinophilic meningitis associated with ciprofloxacin. Am J Med. 1989;87(5):589–90. https://doi.org/10.1016/S0002-9343(89)80620-5
39. Feinmann L. Drug-induced lung disease: pulmonary eosinophilia and sulphonamides. Proc R Soc Med. 1975;68(7):440–1.
40. Sovijärvi ARA, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin induced acute, subacute and chronic pulmonary reactions. A report of 66 cases. Scand J Resp Dis. 1977;58(1):41–50.
41. Davidson AC, Bateman C, Shovlin C, Marrinan M, Burton GH, Cameron IR. Pulmonary toxicity of malaria prophylaxis. BMJ. 1989;297(6658):1240–1. https://doi.org/10.1136/bmj.297.6658.1240
42. Janier M, Guillevin L, Badillet G. Pulmonary eosinophilia associated with dapsone. Lancet. 1994;343(8901):860–1. https://doi.org/10.1016/S0140-6736(94)92066-4
43. Wong PC, Yew WW, Wong CF, Choi HY. Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement. Eur Respir J. 1995;8(5):866–8.
44. Lee M, Berger HW. Eosinophilia caused by rifampin. Chest. 1980;77(4):579. https://doi.org/10.1378/chest.77.4.579b
45. Lange P, Oun H, Fuller S, Turney JH. Eosinophilic colitis due to rifampicin. Lancet. 1994;344(8932):1296–7.https://doi.org/10.1016/S0140-6736(94)90782-X
46. Zhang SN, He QX, Yang NB, Ni SL, Lu MQ. Isoniazid-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Presenting as acute eosinophilic myocarditis. Intern Med. 2015;54(10):1227–30. https://doi.org/10.2169/internalmedicine.54.3511.
47. Kayanakis JG, Giraud P, Fauvel JM, Bounhoure JP. Eosinophilia during captopril treatment. Lancet. 1980;316(8200):923. https://doi.org/10.1016/S0140-6736(80)92085-1
48. Watanabe K, Nishimura K, Shiode M, Sekiya M, Ikeda S, Inoue Y, Iwanaga C. Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. Intern Med. 1996;35(2):142–5. https://doi.org/10.2169/internalmedicine.35.142
49. Barnes JN, Davies ES, Gent CB. Rash, eosinophilia and hyperkalaemia associated with enalapril. Lancet. 1983;322(8340):41–2. https://doi.org/10.1016/S0140-6736(83)90020-X
50. Benard A, Melloni B, Gosselin B, Bonnaud F, Wallaert B. Perindopril-associated pneumonitis. Eur Respir J. 1996;9(6):1314–6. https://doi.org/10.1183/09031936.96.09061314
51. Wathen CG, MacDonald T, Wise LA, Boyd SM. Eosinophilia associated with spironolactone. Lancet. 1986;1(8486):919–20. https://doi.org/10.1016/s0140-6736(86)91026-3
52. Dominguez EA, Hamill RJ. Drug-induced fever due to diltiazem. Arch Intern Med. 1991;151(9):1869–70. https://doi.org/10.1001/archinte.1991.00400090141026
53. Dukes MNG. Meylers side effects of drugs. 13th ed. Oxford: Elsevier Press; 1996.
54. Marcos Sánchez F, Aparicio Martínez JC, Durán Pérez-Navarro A. Eosinophilia caused by low-molecular-weight heparin. An Med Interna. 1992;9(5):256.
55. Taliercio CP, Olney BA, Lie JT. Myocarditis related to drug hypersensitivity. Mayo Clin Proc. 1985;60(7):463–8. https://doi.org/10.1016/S0025-6196(12)60870-2
56. Bacon HM. Eosinophilia associated with chlorpromazine therapy. Am J Psychiatry. 1964;120(9):915–6. https://doi.org/10.1176/ajp.120.9.915
57. Shear MK. Chlorpromazine-induced PIE syndrome. Am J Psychiatry. 1978;135(4):492–3. https://doi.org/10.1176/ajp.135.4.492
58. Keshaven MS, Kennedy JS, eds. Adverse hematological effects in drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation; 1992.
59. Amsterdam JD. Loeffler’s syndrome: an uncommon adverse reaction to imipramine. Int Clin Psychopharmacol. 1986;1(3):260–2.
60. Salerno SM, Strong JS, Roth BJ, Sakata V. Eosinophilic pneumonia and respiratory failure associated with a trazodone overdose. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2170–2. https://doi.org/10.1164/ajrccm.152.6.8520792
61. Anderson BN, Henrikson IR. Jaundice and eosinophilia associated with amitriptyline. J Clin Psychiatry. 1978;39(9):730–1.
62. Hartzema AG, Porta MS, Tilson HH, Milburn DS, Myers CW. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome. DICP. 1991;25(11):1259–62. https://doi.org/10.1177%2F106002809102501116
63. CSM/MCA. L-Tryptophan (Optimax): limited availability for resistant depression. Current Problems in Pharmacovigilance. 1994;20:2.
64. Kaufman LD, Gruber BL, Gregersen PK. Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet. 1991;337(8749):1071–4. https://doi.org/10.1016/0140-6736(91)91717-9
65. Swygert LA, Maes EF, Sewell LE, Miller L, Falk H, Kilbourne EM. Eosinophilia-myalgia syndrome: results of national surveillance. JAMA. 1990;264(13):1698–703. https://doi.org/10.1001/jama.1990.03450130070029
66. Weber RW. Adverse drug effects and the spectrum of eosinophilic pulmonary disorders. Ann Allergy Asthma Immunol. 1995;74(6):451–3.
67. Salzman MB, Valderrama E, Sood SK. Carbamazepine and fatal eosinophilic myocarditis. N Engl J Med. 1997;336(12):878–9. https://doi.org/10.1056/NEJM199703203361216
68. Mahatma M, Haponik EF, Nelson S, Lopez A, Summer WR. Phenytoin-induced acute respiratory failure with pulmonary eosinophilia. Am J Med. 1989;87(1):93–4. https://doi.org/10.1016/S0002-9343(89)80490-5
69. Lazoglu AH, Boglioli LR, Dorsett B, Macris NT. Phenytoin-related immunodeficiency associated with Loеffler’s syndrome. Ann Allergy Asthma Immunol. 1995;74(6):479–82.
70. Kaufman J, O’Shaughnessy I. Eosinophilic pleural effusion associated with valproic acid administration. South Med J. 1995;88(8):881–2. http://dx.doi.org/10.1097/00007611-199508000-00023
71. Rich MW, Thomas RA. A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Chest. 1997;111(6):1767–9. https://doi.org/10.1378/chest.111.6.1767
72. Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia: review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med. 1992;152(7):1521–4. https://doi.org/10.1001/archinte.1992.00400190139026
73. Khalil H, Molinary E, Stoller JK. Diclofenac (Voltaren)-induced eosinophilic pneumonitis: case report and review of the literature. Arch Intern Med. 1993;153(14):1649–52. https://doi.org/10.1001/archinte.1993.00410140031004
74. Quinn JP, Weinstein RA, Caplan LR. Eosinophilic meningitis and ibuprofen therapy. Neurology. 1984;34(1):108. https://doi.org/10.1212/WNL.34.1.108
75. Edelman J, Mastaglia GL, Owen ET. The clinical significance of eosinophilia during gold salt therapy in rheumatoid arthritis. Aust N Z J Med.1981;11:723.
76. Cooke N, Bamji A. Gold lung. Rheumatology. 1981;20(3):129–35. https://doi.org/10.1093/rheumatology/20.3.129
77. Andreu V, Bataller R, Caballería J, Rodés J. Acute eosinophilic pneumonia associated with ranitidine. J Clin Gastroenterol. 1996;23(2):160–2.https://doi.org/10.1097/00004836-199609000-00023
78. Gafter U, Komlos L, Weinstein T, Zevin D, Levi J. Thrombocytopenia, eosinophilia, and ranitidine. Ann Intern Med. 1987;106(3):477. https://doi.org/10.7326/0003-4819-106-3-477_1
79. Tishler M, Abramov AL. Cimetidine-induced eosinophilia. Drug Intell Clin Pharm. 1985;19(5):377–8. https://doi.org/10.1177%2F106002808501900510
80. Smith JD, Chang KL, Gums JG. Possible lansoprazole-induced eosinophilic syndrome. Ann Pharmacother. 1998;32(2):196–200. https://doi.org/10.1345/aph.17190
81. D’adamo G, Spinelli C, Forte F, Gangeri F. Omeprazole-induced acute interstitial nephritis. Ren Fail. 1997;19(1):171–5. https://doi.org/10.3109/08860229709026272
82. Timmer R, Duurkens VA, Van Hees PA. Sulphasalazine-induced eosinophilic pneumonia. Neth J Med. 1992;41(3–4):153–7.
83. Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol. 1996;91(5):1039–40.
84. Bell RJM. Pulmonary infiltration with eosinophils caused by chlorpropamide. Lancet. 1964;283(7345):1249–50. https://doi.org/10.1016/S0140-6736(64)91872-0
85. Diffee JJ 3rd, Hayes JM, Montesi SA, Greene WL, Milnor PJr. Chlorpropamide-induced pulmonary infiltration and eosinophilia with multisystem toxicity. J Tenn Med Assoc. 1986;79(2):82–4.
86. Parker PH, GhishanFK, Shanks D, Greene HL. Eosinophilia associated with cholestyramine. Clin Pediatr (Phila). 1981;20(10):675–6.
87. Weller PF. Eosinophilia and eosinophil-related disorders. In: Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FE, eds. Middleton's Allergy: Principles and Practice. 6th ed. Philadelphia: Mosby; 2003. Р. 1105–26.
88. Falchi L, Verstovsek S. Eosinophilia in hematologic disorders. Immunol Allergy Clin North Am. 2015;35(3):439–52. https://doi.org/10.1016/j.iac.2015.04.004
89. Teragaki M, Kawano H, Makino R, Inoue K, Sai Y, Hosono M, et al. A case of warfarin-induced eosinophilia. Intern Med. 2012;51(12):1627–9. https://doi.org/10.2169/internalmedicine.51.7138
90. Pfitzenmeyer P, Meier M, Zuck P, Peiffer G, Masson P, Turcu A, et al. Piroxicam induced pulmonary infiltrates and eosinophilia. J Rheumatol. 1994;21(8):1573–7.
91. Bando T, Fujimura M, Noda Y, Hirose J, Ohta G, Matsuda T. Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy and pleural effusion. Intern Med. 1994;33(3):177–9. https://doi.org/10.2169/internalmedicine.33.177
92. Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med. 1992;152(9):1913–9. https://doi.org/10.1001/archinte.1992.00400210133023
93. Bain GA, Flower CD. Pulmonary eosinophilia. Eur J Radiol. 1996;23(1):3–8. https://doi.org/10.1016/0720-048X(96)01029-7
94. Martin DM, Goldman JA, Gilliam J, Nasrallah SM. Gold-induced eosinophilic enterocolitis: response to oral cromolyn sodium. Gastroenterology. 1981;80(6):1567–70. https://doi.org/10.1016/0016-5085(81)90274-2
Рецензия
Для цитирования:
Остроумова О.Д., Шахова Е.Ю., Кочетков А.И. Лекарственно-индуцированная эозинофилия. Безопасность и риск фармакотерапии. 2019;7(4):176-189. https://doi.org/10.30895/2312-7821-2019-7-4-176-189
For citation:
Ostroumova O.D., Shahova E.Yu., Kochetkov A.I. Drug-Induced Eosinophilia. Safety and Risk of Pharmacotherapy. 2019;7(4):176-189. (In Russ.) https://doi.org/10.30895/2312-7821-2019-7-4-176-189